Managing atherogenic dyslipidaemia and diabetic retinopathy in type 2 diabetes
Description
In this Product Explainer, Endocrinologist Prof Richard O’Brien explains the role of Fenofibrate in reducing the progression of diabetic retinopathy in patients with type 2 diabetes (5 mins).
expert
Prof Richard O'Brien
Endocrinologist; Clinical Dean of Medicine, University of Melbourne, Austin Clinical School; Director of Graduate Programs, Melbourne Medical School; Senior Endocrinologist and Director, Lipid Service, Austin Health
